

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.2D4APPLICATION NO.  
10/607,035SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Clarence N. Ahlem, et alFILING DATE  
June 25, 2003GROUP  
1617

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,670,349	12-30-03	Nyce			01-20-00
	6,372,732	04-16-02	Lardy et al.			05-27-99
	6,207,703	03-27-01	Ponikau			10-22-98
	6,172,088	01-09-01	Simpkins et al.			11-24-98
	6,046,185	04-02-00	Burgoyne et al.			07-10-97
	6,087,351	07-11-00	Nyce			05-22-97
	5,837,713	11-17-98	Gleich			
	5,660,835	08-26-97	Nyce			
	5,641,768	06-24-97	Loria			
	5,506,221	04-09-96	Anderson et al.			
	5,405,842	04-11-95	Silverman			
	5,116,829	05-26-92	Hori et al.			
	4,897,390	01-30-90	Ruhe			
	4,628,052	12-09-86	Peat			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.)
	Auci D, et al., Anti-inflammatory and immune regulatory properties of 5-androsten-3 $\beta$ ,17 $\beta$ -diol (HE2100) and synthetic analogue HE3204 Implications for treatment of autoimmune diseases, <i>Ann. N.Y. Acad. Sci.</i> , 1051:730 – 742 2005
	Offner H, A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse, <i>Clin. Immun.</i> , 110:181 – 190 2004

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.